Ramipril

How to order Ramipril

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Ramipril on Prescriptsy

Ramipril is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension (high blood pressure), heart failure, and to reduce cardiovascular risk.

It is one of the most widely prescribed medicines in the UK, with millions of prescriptions dispensed annually.

Ramipril works by blocking the conversion of angiotensin I to angiotensin II, a hormone that causes blood vessels to constrict and promotes salt and water retention.

By reducing angiotensin II levels, ramipril relaxes blood vessels, lowers blood pressure, and reduces the workload on the heart.

Ramipril is available as capsules and tablets in strengths of 1.25 mg, 2.5 mg, 5 mg, and 10 mg.

It is a prescription-only medicine (POM) in the United Kingdom.

Hypertension affects approximately 1 in 4 adults in England and is the single largest risk factor for cardiovascular disease, including stroke, myocardial infarction, heart failure, and chronic kidney disease.

Many people with high blood pressure have no symptoms, which is why it is sometimes called the "silent killer." Untreated hypertension causes progressive damage to the heart, blood vessels, kidneys, and brain over years.

Effective blood pressure management with medicines such as ramipril, combined with lifestyle changes, dramatically reduces the risk of these serious complications.

This page provides a comprehensive clinical guide to ramipril, including how it works, dosage instructions, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about ramipril

Before reading further, please note these essential safety points.

• Ramipril must not be taken during pregnancy. It can cause serious harm to the developing baby. If you become pregnant, stop ramipril immediately and contact your prescriber.
• If you develop swelling of your face, lips, tongue, or throat, stop ramipril immediately and call 999. This may be angioedema, a rare but potentially life-threatening reaction.
• Do not take ramipril with other medicines that block the renin-angiotensin system (ARBs, aliskiren) without specialist advice.
• Regular blood tests (kidney function, potassium) are needed during treatment.
• Tell your prescriber about all medicines you take, including over-the-counter painkillers such as ibuprofen.

Understanding hypertension and the renin-angiotensin system

Blood pressure is the force of blood pushing against the walls of the arteries as the heart pumps.

It is expressed as two numbers: systolic pressure (the pressure when the heart contracts) and diastolic pressure (the pressure when the heart relaxes between beats).

Normal blood pressure is generally below 140/90 mmHg in a clinical setting (or below 135/85 mmHg on ambulatory or home monitoring).

NICE guideline NG136 defines hypertension as a clinic blood pressure of 140/90 mmHg or higher, confirmed by ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM) averaging 135/85 mmHg or higher.

The renin-angiotensin-aldosterone system (RAAS) is one of the body's principal blood-pressure-regulating mechanisms.

When blood pressure or renal perfusion drops, the kidneys release renin, which converts angiotensinogen (from the liver) to angiotensin I.

Angiotensin-converting enzyme (ACE), found predominantly in the lungs, then converts angiotensin I to angiotensin II.

Angiotensin II is a powerful vasoconstrictor that also stimulates the release of aldosterone from the adrenal cortex, promoting sodium and water retention by the kidneys.

These actions together raise blood pressure. In hypertension, the RAAS is often inappropriately activated, contributing to sustained vasoconstriction, volume overload, and end-organ damage.

How ramipril works

Ramipril is a prodrug that is converted in the liver to its active form, ramiprilat, by hepatic esterases.

Ramiprilat binds to the active site of ACE and inhibits it, preventing the conversion of angiotensin I to angiotensin II.

This results in reduced vasoconstriction, decreased aldosterone secretion, and increased sodium and water excretion, collectively lowering blood pressure.

Ramiprilat also inhibits the breakdown of bradykinin, a peptide that promotes vasodilation through the release of nitric oxide and prostacyclin from the vascular endothelium.

The increased bradykinin levels contribute to the blood-pressure-lowering effect but are also responsible for the ACE inhibitor cough and, rarely, angioedema.

Beyond blood pressure reduction, ramipril has additional cardiovascular and renal protective effects.

It reduces left ventricular hypertrophy (thickening of the heart muscle that occurs in response to sustained high blood pressure), improves endothelial function, reduces oxidative stress, and decreases glomerular capillary pressure in the kidneys, slowing the progression of chronic kidney disease and reducing proteinuria.

These pleiotropic effects help explain why ACE inhibitors have been shown to reduce cardiovascular events and mortality in several landmark trials.

Clinical evidence and the HOPE trial

Ramipril has one of the strongest evidence bases of any cardiovascular medicine.

The landmark Heart Outcomes Prevention Evaluation (HOPE) trial, published in 2000 in the New England Journal of Medicine, randomised 9,297 high-risk patients aged 55 years or older (with vascular disease or diabetes plus one other cardiovascular risk factor) to ramipril 10 mg daily or placebo.

Over a mean follow-up of 5 years, ramipril reduced the combined primary endpoint of myocardial infarction, stroke, and cardiovascular death by 22% (relative risk reduction).

It also reduced the risk of all-cause mortality by 16%, stroke by 32%, and myocardial infarction by 20%.

These benefits were observed across all subgroups, including patients whose blood pressure was not elevated at baseline, suggesting that ramipril's cardiovascular protective effects extend beyond blood pressure lowering alone.

The AIRE (Acute Infarction Ramipril Efficacy) trial demonstrated that ramipril, started 3 to 10 days after myocardial infarction in patients with clinical evidence of heart failure, reduced all-cause mortality by 27% over a mean of 15 months.

These findings established ramipril as a key component of post-MI management and heart failure treatment.

NICE guideline NG136 (Hypertension in adults: diagnosis and management) recommends ACE inhibitors as first-line treatment for hypertension in patients under 55 (or those with type 2 diabetes at any age).

For patients aged 55 and over, or those of Black African or Afro-Caribbean descent, a calcium channel blocker is recommended first-line, with an ACE inhibitor added at Step 2 if needed.

NICE guideline NG106 (Chronic heart failure in adults) recommends ACE inhibitor titration to the maximum tolerated evidence-based dose in all patients with heart failure with reduced ejection fraction (HFrEF).

Ramipril compared with other ACE inhibitors and ARBs

Several ACE inhibitors are available in the UK, including enalapril, lisinopril, perindopril, and captopril.

All work by the same mechanism, but they differ in pharmacokinetics, potency, and clinical evidence.

Ramipril is the most commonly prescribed ACE inhibitor in the UK, largely because of the HOPE trial evidence. Perindopril has strong evidence from the EUROPA and ASCOT trials.

Lisinopril (from the ATLAS and GISSI-3 trials) is also widely used.

ARBs (losartan, candesartan, valsartan) block the angiotensin II receptor directly and are used as alternatives in patients who develop an ACE inhibitor cough or angioedema.

ARBs do not increase bradykinin and therefore rarely cause cough or angioedema.

Dosage and administration

Ramipril capsules or tablets should be taken once daily at the same time each day, swallowed whole with water, with or without food. Dosing varies by indication.

For hypertension: start at 1.25 mg once daily, increase at 2 to 4 week intervals to 2.5 to 5 mg once daily (maximum 10 mg).

For heart failure: start at 1.25 mg once daily, titrate to a target of 10 mg once daily.

Post-MI: start at 2.5 mg twice daily from day 3, increasing to 5 mg twice daily after 2 days.

For cardiovascular prevention: start at 2.5 mg once daily, titrate to 10 mg once daily over 2 to 3 weeks.

The first dose may cause a noticeable drop in blood pressure, especially in patients on diuretics, those who are dehydrated, or those with heart failure.

Consider taking the first dose at bedtime and monitoring carefully.

Blood pressure, renal function, and potassium should be checked before starting, 1 to 2 weeks after each dose change, and at least annually during maintenance.

Side effects of ramipril

ACE inhibitor cough

A persistent dry cough occurs in approximately 5% to 15% of patients and is the most common reason for discontinuing ACE inhibitor therapy.

It is caused by bradykinin accumulation in the lungs and is more common in women and non-smokers.

The cough typically resolves within 1 to 4 weeks of stopping ramipril.

If the cough is intolerable, your prescriber will usually switch you to an ARB (losartan, candesartan, or valsartan), which provides similar cardiovascular benefits without the cough.

Hypotension and dizziness

Dizziness, light-headedness, and fainting can occur, particularly with the first dose, after dose increases, or in patients who are dehydrated or taking diuretics.

Rising slowly from a sitting or lying position helps. If severe dizziness or fainting occurs, contact your prescriber.

Hyperkalaemia

Ramipril can raise serum potassium levels by reducing aldosterone secretion.

The risk is higher in patients with renal impairment, diabetes, or those taking potassium-sparing diuretics, potassium supplements, or trimethoprim. Regular blood tests monitor potassium levels.

Symptoms of high potassium include muscle weakness, tiredness, and irregular heartbeat. Potassium above 5.5 mmol/L requires dose reduction or discontinuation.

Renal effects

A small rise in serum creatinine (up to 30% above baseline) is expected when starting ACE inhibitors and reflects the reduction in glomerular filtration pressure.

A rise greater than 30% should prompt investigation, dose reduction, and exclusion of renal artery stenosis.

ACE inhibitors are contraindicated in bilateral renal artery stenosis, where they can cause acute renal failure.

Angioedema

Angioedema is a rare (estimated 0.1% to 0.7% of ACE inhibitor users) but potentially life-threatening adverse effect.

It causes swelling of the deeper layers of the skin, most commonly affecting the face, lips, tongue, and throat.

Laryngeal angioedema can obstruct the airway and be fatal if not treated promptly. Angioedema can occur at any point during treatment, including after years of uneventful use.

The risk is 2 to 4 times higher in patients of Black African or Afro-Caribbean descent. If angioedema occurs, stop ramipril permanently and call 999.

Never restart an ACE inhibitor after angioedema.

Other side effects

Less common side effects include altered taste (metallic or loss of taste), skin rash, headache, fatigue, nausea, and diarrhoea. Rarely, blood disorders (neutropenia, agranulocytosis) may occur, particularly in patients with autoimmune diseases or those taking immunosuppressants.

When to seek medical advice

Contact your GP or call NHS 111 if you develop a persistent dry cough, dizziness, muscle weakness, or an unexplained rash.

Call 999 immediately if you experience swelling of the face, lips, tongue, or throat, sudden severe dizziness or collapse, chest pain, or difficulty breathing.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Absolute contraindications

Ramipril is contraindicated in pregnancy, history of angioedema (from ACE inhibitor, ARB, or hereditary/idiopathic), bilateral renal artery stenosis, haemodynamically significant aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy, and concomitant use with aliskiren in patients with diabetes or renal impairment.

Pregnancy and breastfeeding

ACE inhibitors are absolutely contraindicated in pregnancy. Exposure during the second and third trimesters causes fetal renal failure, oligohydramnios, and skull defects.

First-trimester exposure may increase the risk of cardiovascular and neural tube defects. Women of childbearing potential must use reliable contraception.

If pregnancy occurs, stop ramipril immediately and switch to a safe alternative (labetalol, nifedipine, or methyldopa as per NICE NG133).

Ramipril is not recommended during breastfeeding due to limited safety data.

First-dose precautions

Patients at highest risk of first-dose hypotension include those with heart failure (especially if on high-dose diuretics), patients who are dehydrated, elderly patients, and those on concomitant antihypertensive therapy.

Consider reducing or stopping diuretics for 2 to 3 days before starting ramipril, starting at the lowest dose, and monitoring blood pressure for several hours after the first dose.

Drug interactions

Avoid dual RAAS blockade (combining ACE inhibitors with ARBs or aliskiren) due to increased risks of hyperkalaemia, renal failure, and hypotension.

NSAIDs reduce the efficacy of ramipril and increase renal and hyperkalaemia risk. Potassium-sparing diuretics and potassium supplements increase hyperkalaemia risk.

Lithium clearance is reduced by ACE inhibitors; monitor lithium levels closely. Diuretics can potentiate the hypotensive effect of ramipril; adjust doses accordingly.

Ethnic considerations

ACE inhibitors tend to be less effective as monotherapy for blood pressure lowering in patients of Black African or Afro-Caribbean descent.

NICE NG136 recommends a calcium channel blocker as first-line treatment in this population, with an ACE inhibitor added at Step 2 if needed, or if the patient has diabetes or proteinuria.

The risk of ACE inhibitor-associated angioedema is also higher in this group.

Lifestyle advice for blood pressure management

Medication is most effective when combined with lifestyle changes.

NICE recommends reducing salt intake to less than 6 g per day, maintaining a healthy weight (BMI 20 to 25), taking regular exercise (at least 150 minutes of moderate activity per week), limiting alcohol to 14 units per week, eating a balanced diet rich in fruit, vegetables, and wholegrains (the DASH dietary pattern has strong evidence for blood pressure reduction), stopping smoking, and managing stress.

Home blood pressure monitoring helps track progress and supports treatment decisions. Aim for a target below 135/85 mmHg on home readings, or below 140/90 mmHg in clinic.

How to get ramipril in the UK

Ramipril is available on NHS prescription from your GP or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Ramipril is a generic medicine and is widely available at low cost.

Patients with certain long-term conditions may be eligible for a medical exemption certificate, which provides free prescriptions.

Sources

• Ramipril capsules, Summary of Product Characteristics (EMC)
• Ramipril, British National Formulary (BNF)
• NICE NG136: Hypertension in adults, diagnosis and management
• NICE NG106: Chronic heart failure in adults, diagnosis and management
• Ramipril, NHS
• MHRA Yellow Card Scheme